Clinical trials
Phase 1 Non-alcoholic Fatty Liver Disease trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
161 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 6 |
| 2016 | 6 |
| 2017 | 8 |
| 2018 | 13 |
| 2019 | 8 |
| 2020 | 19 |
| 2021 | 23 |
| 2022 | 10 |
| 2023 | 26 |
| 2024 | 11 |
| 2025 | 8 |
| 2026 | 9 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 116 |
| Recruiting | 13 |
| Unknown status | 10 |
| Terminated | 8 |
| Withdrawn | 6 |
| Not yet recruiting | 5 |
| Active, not recruiting | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 9 |
| AstraZeneca | 8 |
| Columbia University | 8 |
| Novo Nordisk A/S | 7 |
| Corcept Therapeutics | 5 |
| Eccogene | 5 |
| Altimmune, Inc. | 4 |
| Bristol-Myers Squibb | 4 |
| Enanta Pharmaceuticals, Inc | 4 |
| Sunshine Lake Pharma Co., Ltd. | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Non-alcoholic Fatty Liver Disease | 161 |
| Obesity | 18 |
| Fatty Liver | 12 |
| Diabetes Mellitus, Type 2 | 8 |
| Overweight | 8 |
| Diabetes Mellitus | 7 |
| Hyperinsulinism | 7 |
| Insulin Resistance | 7 |
| Liver Diseases | 6 |
| Prediabetic State | 6 |
Trials
Showing 51 to 75 of 161. Each trial links to its page on Pharma Observatory.
61 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.